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Magnesium is the fourth most abundant cation in the body. It has several functions in the human body including its role as a
cofactor for more than 300 enzymatic reactions. Several studies have shown that hypomagnesemia is a common electrolyte
derangement in clinical setting especially in patients admitted to intensive care unit where it has been found to be associated
with increase mortality and hospital stay. Hypomagnesemia can be caused by a wide range of inherited and acquired diseases. It
can also be a side effect of several medications. Many studies have reported that reduced levels of magnesium are associated
with a wide range of chronic diseases. Magnesium can play important therapeutic and preventive role in several conditions such
as diabetes, osteoporosis, bronchial asthma, preeclampsia, migraine, and cardiovascular diseases. This review is aimed at
comprehensively collating the current available published evidence and clinical correlates of magnesium disorders.
1. Introduction
Magnesium (Mg2+) has several functions in the human
body. It acts as a cofactor for more than 300 enzymes,
regulating a number of fundamental functions such as
muscle contraction, neuromuscular conduction, glycemic
control, myocardial contraction, and blood pressure [1, 2].
Moreover, magnesium also plays a vital role in energy
production, active transmembrane transport for other ions,
synthesis of nuclear materials, and bone development [2].
Furthermore, magnesium deficiency has been associated
with a wide range of diseases. Additionally, many studies
have demonstrated beneficial effects of magnesium supple-
mentation. In this review, the magnesium cycle in the
human body, magnesium deficiency and its causes, dis-
eases associated with low magnesium, hypermagnesemia,
and the role of magnesium in therapy and prevention will
be discussed.
1.1. Magnesium and Nutrition. According to the United
States Food and Nutrition Board, recommended daily allow-
ance for magnesium is 420mg for adult males and 320mg for
adult females, respectively [3]. Approximately 10% of the
daily magnesium requirement is derived from water. Green
vegetables, nuts, seeds, and unprocessed cereals are rich
sources of magnesium. Also, some magnesium is available
in fruits, fish, meat, and milk products [2].
The majority of the population in the Western countries
consume less than the recommended amount of magnesium,
contributed by the consumption of processed foods, demi-
neralized water, and agricultural practices using soil deficient
in magnesium for growing food [3–5].
2. Magnesium Absorption and Excretion
Magnesium homeostasis is regulated by the intestines, the
bones, and the kidneys [4]. The majority of magnesium is
absorbed by a passive paracellular mechanism in the ileum
and distal parts of the jejunum, while a smaller amount is
actively transported in the large intestine [2, 6]. Around
24–76% of ingested magnesium is absorbed in the gut and
the remaining is eliminated in the feces. The proportion of
absorbed magnesium from the gut depends on the amount
of ingested magnesium [3] and the status of magnesium in
the body [2, 4].
Themagnesium homeostasis is primarily regulated by the
kidneys [4]. The glomeruli filter around 2400mg of magne-
sium per day. About 95% of excreted magnesium is reab-
sorbed, mainly by the thick ascending limb of the loop of
Henle (65%) and to a lesser extent in the distal tubules (30%)
[4, 7]. Only around 100mg of magnesium is excreted in the
urine each day, and the kidneys can regulate the amount
excreted, depending on the serum level of magnesium [4].
Figure 1 illustrates themagnesiumbalance in thehumanbody.
3. Role of Hormones in
Magnesium Homeostasis
Vitamin D, parathyroid hormone (PTH), and estrogen are
hormones that play an important role in magnesium homeo-
stasis (Table 1) [2, 8]. The relationship between PTH and
magnesium is complex and similar to calcium; high serum
magnesium levels suppress the secretion of PTH via activa-
tion of calcium-sensing receptor (CaSR) present on the chief
cells of the parathyroid glands. In contrast, low serum mag-
nesium stimulates PTH secretion.
Magnesium has important role in adenylate cyclase activ-
ity required for cyclic adenosine monophosphate (cAMP)
which is involved in PTH secretion and end organ effects
of PTH. Severe hypomagnesemia (<0.4mmol/L) causes
reduced cAMP levels which can result in reduced secretion
of PTH and increased peripheral resistance [9, 10]. In addi-
tion, molecular studies have suggested that severe hypomag-
nesemia causes blockage of PTH secretion by disinhibition of
G[α] subunits and subsequently activation of the CaSR [11].
This paradoxical effect of hypomagnesemia can result in
hypocalcemia in patients with severe hypomagnesemia [12].
On the other hand, PTH enhances the reabsorption of mag-
nesium in the distal convoluted tubule and the gut and
increases the release of magnesium from the bone [2].
4. Magnesium Storage and Circulation
The total body magnesium in the average adult is around
1000mmol or 24 g, that is, 20mmol/kg of lean body mass
[4]. The bones store about 50–60% of the total magnesium
content while muscles and other soft tissues store around
40–50% [3]. Around one-third of the bone magnesium con-
tent is available for exchange to maintain the levels of extra-
cellular magnesium [4]. Less than 2% of magnesium in the
body is available in serum and red blood cells, accounting
for the extracellular magnesium in the body [3].
5. Magnesium Transcellular Transportation
Due to the very important role of magnesium in the human
body, the levels of cellular magnesium need to be strictly reg-
ulated. Several specific transporters controlling the cellular
movements of magnesium have been identified [13]. Using
the electrochemical gradient of Na+ and through cations
channels, magnesium enters cells via Mg2+/anion cotrans-
port. Eight cation channels have been identified including
transient receptor potential melastatin cation channels 6
and 7 (TRPM6, TRPM7), members 1 and 2 (SLC41A1,
SLC41A2) channels, ancient conserved domain protein 2
(ACDP2), the mitochondrial RNA splicing 2 protein
(Mrs2p), magnesium transporter 1 (MagT1), the human sol-
ute carrier family 41, and paracellin-1 [13]. TRPM7 is the
most selective channel for magnesium, and it has been iden-
tified in the heart, blood vessels, lungs, liver, brain, intestine,
and spleen. It is essential for regulating intracellular magne-
sium level, cell survival, and function [14]. On the other
hand, TRPM6 is mainly responsible for regulating the total
body magnesium level via the kidney and intestines [15].
Mrs2p, SLC41A1, and SLC41A2 are implicated in magne-
sium transportation in the mitochondria and hence have a
regulatory role related to metabolic, cardiovascular, and neu-
rological functions [16]. Magnesium efflux involves several
exchanges including Na+/Mg2+, Ca2+/Mg2+, Mn2+/Mg2+
antiporter, and Cl−/Mg2+ cotransporter [13]. The most
important exchanger is Na+/Mg2+ exchanger which has been
identified in many cells including cardiac and vascular
smooth cells. Several factors have been found to effect the
function of this exchanger such as vasopressin, angiotensin
II, and insulin [13, 17].
6. Role of Magnesium in the Human Body
Magnesium is the fourth most abundant cation in the body
and the second most abundant intracellular cation after
potassium [18]. Magnesium is an essential cofactor for a
diverse metabolic reactions involving more than 300
enzymes within the human body [19]. It acts as counter ion
for the energy-rich ATP and nucleic acids, regulates trans-
membrane transport [20], and has various roles in function
and structure of proteins, nucleic acid, and mitochondria
[2]. Magnesium is an important mineral for bone mineraliza-
tion, muscular relaxation, and several other cellular functions
[18] (Table 2).
7. Assessment of Magnesium Status
In clinical practice, serum magnesium concentration is the
most commonly used test to assess the magnesium status,
and the normal reference range is usually 0.7–1mmol/L
(equivalent to 1.5–2mEq/L or 1.7–2.4mg/dL) [21]. However,
the normal value varies from laboratory to laboratory, and
different studies have used slightly different ranges. This
may partially explain the differences in the prevalence of
magnesium imbalances reported in different groups of
patients with similar characteristics [4].
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Normal serum magnesium does not necessarily mean
adequate content of total body magnesium because only
less than 0.3% of total body magnesium is found in serum
[4]. Serum magnesium is in most places not part of rou-
tine blood tests, and it should be assessed in the relevant
clinical conditions such as arrhythmia, hypokalemia, hypo-
calcemia, diarrhea, and chronic alcoholism that tend to be
associated with magnesium derangement [20]. Assessment
is also recommended if the patient is critically ill or when
being administered certain medications known to cause
hypomagnesemia. Table 3 lists other more accurate but lesser
used measures of assessing magnesium status [2, 22].
8. Hypomagnesemia
Several studies have shown that hypomagnesemia is a com-
mon electrolyte derangement in clinical setting especially in




































Figure 1: Magnesium balance in the human body.
Table 1: Role of vitamins and hormones in magnesium homeostasis.
Hormone/vitamin Role of hormones/vitamins Comments
Vitamin D
1,25-Dihydroxyvitamin D3 can stimulate
intestinal magnesium absorption.
Mg is required for metabolism of vitamin D in the liver and the
kidneys and also for its transportation in serum.
PTH
Helps in the reabsorption of Mg in the kidney,
absorption in the gut, and release from
the bone.
Hypercalcemia interferes with the role of PTH
in magnesium regulation.
Estrogen
Enhances Mg reabsorption in the kidney and
absorption in the gut by stimulating
TRPM6 expression.
Mg: magnesium; PTH: parathyroid hormone.
Table 2: Role of magnesium in the human body.
Cofactor for enzymes involved in
Protein synthesis, muscle and nerve transmission, neuromuscular
conduction, and blood glucose and blood pressure regulation.
Role in active transport
Facilitates active transport of calcium and potassium ions across
cell membranes, which is essential for the conduction of nerve
impulses, muscle contraction, maintaining vasomotor tone, and
normal heart rhythm.
Structural roles
Important for the structure of bones, proteins, many enzymes,
mitochondria, DNA, and RNA.
Role in immunological functions
Involved in macrophage activation, adherence, and bactericidal
activity of granulocyte oxidative burst, lymphocyte proliferation,
and endotoxin binding to monocytes.
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found to be associated with increased mortality and hospital
stay [23–25] (Table 4).
8.1. Symptoms of Hypomagnesemia. Symptoms of magne-
sium deficiency can be nonspecific and usually overlap with
symptoms of other electrolyte imbalances. The severity of
symptoms and signs depends on the degree of magnesium
depletion and rate of magnesium decline. The symptoms
usually occur when serum magnesium levels fall below
0.5mmol/L (1.2mg/dL) [26]. The clinical manifestations of
hypomagnesemia may affect every system including neuro-
muscular, cardiovascular, renal, and gastrointestinal systems
(Table 5) [4, 18]. The impact of chronic magnesium
(Figure 2) depletion will be discussed in more depth later.
8.2. Causes of Hypomagnesemia. Causes of hypomagnesemia
can be categorized into genetic causes [19] (Table 6) and
acquired causes. The acquired causes can be attributed to
decreased oral intake or GI absorption, increased renal loss,
or redistribution triggered by severe illness [2]. Several med-
ications are also known to influence serum magnesium levels
by different mechanisms [4, 6, 27–31] (Table 7).
8.2.1. Decreased Intake. Several dietary surveys have shown
that people in North America and Europe consume less than
recommended daily allowance (RDA) for magnesium as a
result of food processing and the use of poor soil for agricul-
ture [2, 5, 32]. Hypomagnesemia can also occur in times of
prolonged fasting, total parenteral nutrition, or prolonged
nasogastric suctioning [33].
8.2.2. Impaired Gastrointestinal Absorption. Impaired gastro-
intestinal absorption of magnesium can be caused by a
number of factors including chronic diarrhea, pancreatic
insufficiency, celiac disease, chronic alcoholism, inflamma-
tory bowel diseases, and short gut syndrome [26].
8.2.3. Redistribution and Intracellular Magnesium Shift.
Acute pancreatitis associated with fat necrosis can cause
hypomagnesemia via saponification. Additionally, there are
certain conditions that can result in an intracellular shift
in magnesium distribution. These include the refeeding
syndrome, pregnancy, lactation, and cardiopulmonary
surgeries [26].
8.2.4. Increased Renal Loss of Magnesium. Conditions such as
diabetes mellitus, acute tubular necrosis, postobstructive
diuresis, post kidney transplantation, excessive volume
expansion, and chronic metabolic acidosis can all lead to
hyperfiltration and increased renal loss of magnesium
[26, 27]. Reduced renal reabsorption of magnesium can
be triggered by hypokalemia, hypercalcemia, and hypopho-
sphatemia [26]. Chronic alcoholism has been associated
with reversible renal tubular dysfunction and hypomagne-
semia [34]. Moreover, there are many genetic conditions
(Table 6) and medications (Table 7) that have been asso-
ciated with reduced renal reabsorption of magnesium.
8.2.5. Drug-Induced Hypomagnesemia. Around 50 medica-
tions have been found to cause hypomagnesemia [4, 6, 27–
31, 35, 36]. Table 7 lists the most commonly prescribed
medications associated with hypomagnesemia.
8.3. Hypomagnesemia in Critically Ill Patients. Hypomagne-
semia is common in critically ill patients admitted to ICU,
with a prevalence between 9% and 79% in different observa-
tional studies [37–43]. It is more common in postoperative
ICU patients. Hypomagnesemia in critically ill patients
might be explained by many factors such as impaired magne-
sium absorption secondary to impaired gastrointestinal
activity, malnutrition, diabetes mellitus, and other electrolyte
imbalances (e.g., hypokalemia and hypocalcemia) along with
medications (e.g., loop diuretics, gentamycin, and proton
pump inhibitors) [41]. According to previous studies, hypo-
magnesemia has been shown to be strongly associated with
the increased need for mechanical ventilation, increased risk
of sepsis and lactic acidosis, prolonged ICU stay, and increase
in mortality [43–46]. A meta-analysis including 6 studies
with total of 1550 participant reported that there was a signif-
icantly higher risk of mortality (relative risk 1.9), need for
mechanical ventilation (relative risk 1.56), and prolonged
ICU stay in patients admitted to ICU with hypomagnesemia
[47]. Several studies have shown a weak relationship between
Table 3: Assessment of magnesium status.
Test Comments
Serum magnesium
Sometimes not adequate since less than 0.3% of total body magnesium is found in serum.
However, it is easy, accessible, and cheap.
24 hours excretion in urine or the fractional
excretion of magnesium
Helps in differentiating renal wasting of magnesium from inadequate intake or poor
absorption as an etiology for hypomagnesemia.
Magnesium loading test
Identifies patients with normomagnesic magnesium deficiency.
Assesses intestinal absorption of magnesium.
Indirectly assesses bone status of magnesium.
Magnesium concentration in RBCs Can give early indication of magnesium deficiency.
Isotopic analysis of magnesium Assesses the absorption of magnesium from the gastrointestinal tract in research setting.
Ionized magnesium
More accurate, especially in critically ill patients with rapid change in hemodynamics.
Not effected by low albumin.
RBCs: red blood cell counts.
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serum magnesium concentration and total body magnesium
in critically ill patients. Measuring ionized magnesium was
found to better represent the actual magnesium status in this
group of patients [46, 48].
Due to the high prevalence of hypomagnesemia in ICU
patients, it is recommended to monitor serum magnesium
closely [41, 49]. Intravenous magnesium sulfate replacement
has been shown to have antiarrhythmic and neuroprotective
effect and might be associated with decrease mortality and
length of ICU stay [50–53].
8.4. Hypo- and Hypermagnesemia in Hospitalized Patients.
There are only a limited number of studies that have analyzed
the prevalence of hypo- and hypermagnesemia in hospital-
ized patients in general, including non-ICU patients. A recent
study fromMayo Clinic included all patients (288,120 admis-
sions) admitted to the hospital between 2009 and 2013 and
assessed the prevalence and prognostic impact of dysmag-
nesemia [25]. Magnesium status was evaluated in only
40% of admitted patients on the first day of admission.
Of the analyzed patients, 31.5% had hypermagnesemia
(Mg> 0.91mmol/L) while 20.2% had hypomagnesemia,
which was more common in patients with oncologic/
hematological disorders. On the other hand, hypermagne-
semia was commonly observed for patients with cardiovas-
cular diseases, which can be attributed to the increased
trend of consuming magnesium supplements in this group
due to increased awareness of the beneficial impacts of
magnesium on the cardiovascular system. The study found
that both hypomagnesemia and hypermagnesemia were
associated with increased risk of hospital mortality and
prolonged length of stay when adjusted for all variables
except the admission diagnosis. Since Mayo Clinic is a major
referral center for the entire US continent, some of these
results may not be generalizable to other hospitals.
9. Hypermagnesemia
Although generally rare, the prevalence of hypermagnesemia
in hospitalized patients can approach >30%, and similar to
hypomagnesemia, hypermagnesemia has been found to be
associated with higher mortality and longer hospital stay
[25]. Hypermagnesemia is usually iatrogenic and is reported
along with impaired kidney function, bowel disorders, and
old age. Other uncommon causes of hypermagnesemia
include lithium therapy, hypothyroidism, Addison’s disease,
familial hypocalciuric hypercalcemia, and milk alkali syn-
drome [33]. Clinical consequences of hypermagnesemia vary
according the serum magnesium level [54, 55] (Table 8).
10. Hypomagnesemia and Endocrine Diseases
10.1. Diabetes Mellitus.Magnesium is an essential cofactor of
several enzymes involved in carbohydrate metabolism [56].
Magnesium works as an insulin sensitizer by autophosphor-
ylation of insulin receptors and regulating tyrosine kinase
activity on these receptors [57]. In addition, magnesium
blocks entry of calcium into adipocytes through the L-type
calcium channel. Reduced intracellular magnesium level
can lead to increased calcium entry into adipocytes followed
by increase oxidative stress, inflammation, and increase insu-
lin resistance [58, 59]. On the other hand, previous studies
have shown that insulin facilitates shift of magnesium from
the extracellular to the intracellular space [60, 61] and
reduces the tubular reabsorption of magnesium, which can
lead to hypomagnesemia in people with poorly controlled
diabetes and hyperinsulinemia [62].
Magnesium-deficient diet was found to be significantly
associated with reduced insulin-dependent glucose uptake
[63, 64] and increase incidence of diabetes mellitus [65].
Also, several studies have shown inverse relationship
between serummagnesium levels and incidence of type 2 dia-
betes mellitus [65–67]. A meta-analysis examining the rela-
tionship between magnesium intake and type 2 diabetes
involving seven cohort studies with a total of 286,668 partic-
ipants concluded that four out of the seven studies showed a
significant inverse relationship between magnesium intake
and the risk of type 2 diabetes. It was estimated that
100mg/day of magnesium reduces the risk of type 2 diabetes
by 15% [68]. Moreover, magnesium supplements reduced the
Table 4: Prevalence of hypomagnesemia in different populations and under different clinical settings.
Authors Country and year Definition Sample Sample size Prevalence
Chernow [23] USA, 1989 <0.75mmol/L ICU 193 61%
Schimatschek and Rempis [24] Germany, 2001 <0.76mmol/L Unselected population 16,000 14.5%
Cheungpasitporn et al. [25] USA, 2015 <0.70mmol/L Hospitalized patients 65,974 20.2%
ICU: intensive care unit.
Table 5: Clinical and laboratory manifestations of hypomagnesemia.
System Manifestations
Neuromuscular Tremors, muscle fasciculation, muscle spasms and cramps, muscle contractions, numbness, tingling, and weakness.
Central nervous Agitation, depression, sudden change in behavior, encephalopathy, and seizures.
Cardiovascular Cardiac arrhythmia and ECG changes.
Gastrointestinal Loss of appetite, nausea, and vomiting.
Metabolic Hypokalemia and hypocalcemia.
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risk of developing type 2 diabetes in high-risk population,
as demonstrated in a prospective study involved 2582
community-dwelling participants followed up for 7 years
[69]. Oral magnesium supplementation could reduce plasma
glucose levels and improve the glycemic status in a random-
ized controlled trial (RCT) involving 116 adults with
prediabetes and hypomagnesemia [70]. Similar beneficial
effects of oral magnesium have been demonstrated in people
with type 2 diabetes and hypomagnesemia [71]. An observa-
tional study concluded that low serum magnesium was sig-
nificantly associated with higher prevalence of diabetic
nephropathy, and hypomagnesemia can be used as a marker
Risk of migraine. 
Risk of seizure.
Risk of stroke. 
 Risk of cardiac arrhythmia.
 Risk of digoxin toxicity.
 Risk of coronary artery
 disease.
 Mortality and morbidity in
 patient with heart failure.









In patient with CKD hypomagnesmia
is associated with the following: 





Risk of type 2 diabetes mellitus.
Triglycerides and total cholesterol.
HDL.
Oxidative stress.
 Risk of atherosclerosis .
 Risk of hypertension. 
 Vascular tone and resistance.
Risk of osteoporosis :
(i) Formation of large but fragile
(ii) Reduces the vascular supply of
bones. 
(iii) Increases inflammatory cytokines.
(iv) Reduces PTH levels.
(v) Increase in tissue resistance to PTH.
(vi) Decrease in vitamin D levels .
Causes of magnesium-dependent vitamin
D-resistant rickets:
(i) Reduction of the synthesis of vitamin D.
(ii) Reduction of PTH levels. 
Figure 2: Impact of hypomagnesemia.
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for the risk of development of diabetic nephropathy [72].
Additionally, hypomagnesemia was associated with poor
glycemic control [73], reduced HDL cholesterol, increased
triglycerides, and total cholesterol levels [74, 75].
In regard to gestational diabetes, a RCT involving 70
women reported that oral magnesium supplementation
provided multiple beneficial effects on metabolic status and
fetal and pregnancy outcomes [76]. In addition, a recent
RCT demonstrated that oral magnesium supplementation
(250mg/day) to women with gestational diabetes signifi-
cantly reduced fasting plasma glucose compared with pla-
cebo. Moreover, it had beneficial effect on lipid profile by
upregulating gene expression of peroxisome proliferator-
activated receptor gamma (PPAR-γ) and glucose transporter
1 (GLUT-1) and downregulating gene expression of oxidized
low-density lipoprotein receptor (LDLR) [77].
The level of magnesium was found to be lower in patients
with type 1 diabetes mellitus compared to healthy individuals
Table 6: The most common genetic disorders causing hypomagnesemia.
Disorder Inheritance Gene Other features (other than hypomagnesemia)
Hypercalciuric hypomagnesemias Hypercalciuria and nephrocalcinosis
FHHNC type 1 AR CLDN16
Polyuria/polydipsia, elevated serum PTH,
and renal failure
FHHNC type 2 AR CLDN19




AD CASR Hypocalcemia with normal or low PTH
Bartter syndrome










AR SLC12A3 Chondrocalcinosis at older age






and cardiac conduction defects
ADHH: autosomal dominant hypocalcemia with hypocalciuria; ADTKD: autosomal dominant tubulointerstitial kidney disease; FHHNC: familial
hypomagnesemia with hypocalcemia and nephrocalcinosis; RCAD: renal cysts and diabetes; KSS: Kearns-Sayre syndrome; AR: autosomal recessive; AD:
autosomal dominant.
Table 7: Medications associated with hypomagnesemia.
Medications System Pathophysiology
Aminoglycoside antibiotics Renal Impair renal tubular reabsorption± acute tubular necrosis (ATN)
Amphotericin B Renal Renal toxicity and impaired magnesium reabsorption
Antiepidermal growth factor (EGF) receptor (e.g., cetuximab) Renal Impairs magnesium reabsorption
Calcineurin inhibitors (e.g., cyclosporine and tacrolimus) Renal Impair magnesium reabsorption
Platinum derivatives (e.g., cisplatin and carboplatin) Renal Impair magnesium reabsorption
Loop and thiazide diuretics Renal Impair magnesium reabsorption
Pentamidine Renal Impairs magnesium reabsorption
Proton pump inhibitors (PPI) GI
Reduce intestinal absorption of magnesium by downregulating the
TRPM6 transporters.
GI: gastrointestinal.
Table 8: Clinical manifestations of hypermagnesemia.
Serum magnesium levels Manifestations
0.70–1.0mmol/L Normal level.
2.2–3.5mmol/L Nausea, vomiting, facial flushing, urinary retention, ileus, and hypotension.
3.9–5.2mmol/L Somnolence, absence of the deep tendon reflex, and complete heart blockage.
>6.5mmol/L Respiratory depression, paralysis, and complete heart blockage.
>8.7mmol/L Asystole.
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[78]. Hypomagnesemia was also associated with poor glyce-
mic control [79], poor lipid profile [80], and high risk of ath-
erosclerosis [81]. In addition, some studies in type 1 diabetes
have shown a beneficial effect of magnesium supplementa-
tion in improving HbA1c and lipid profile [82] and slowing
the progression of neuropathy [83].
10.2. Metabolic Syndrome. Several studies have linked hypo-
magnesemia with chronic inflammation and the metabolic
syndrome. It has been proposed that hypomagnesemia can
trigger low-grade chronic inflammation by contributing to
activation of leukocyte and macrophage, release of acute-
phase proteins and cytokines, as well as production of free
radicals [59, 84, 85]. In addition, several clinical and epidemi-
ological studies have demonstrated inverse relationships
between serum magnesium and C-reactive protein (CRP)
which is an important marker of inflammation [86–88].
However, it should be taken into account that oxidative stress
has several causes starting with unbalanced diet involving not
only magnesium but many other nutrients related with sim-
ilar diseases than the ones attributed to hypomagnesemia.
Nevertheless, a recent systemic review evaluated the effect
of magnesium supplementation on insulin resistance. Twelve
studies were identified, and it was concluded that oral mag-
nesium supplementation had beneficial effect on insulin
resistance in patients with hypomagnesemia compared to
patients with normal serum magnesium [89]. Moreover, oral
magnesium supplementationmay have positive effect on lipid
profile in individuals with and without diabetes [90, 91]. Fur-
thermore, magnesium supplementation improves metabolic
control and reduces insulin resistance in patients with type 2
diabetes and hypomagnesemia [71].
10.3. Magnesium and Osteoporosis. Bones store around 60%
of total body magnesium, of which 30% is skeletal magne-
sium in the hydration shell or on the surface of hydroxyapa-
tite [92]. Magnesium on the surface of the bones is available
for exchange with serum magnesium. The remaining skeletal
magnesium forms an integral part of the bones, and its
release is dependent on the bone resorption [93].
Low serum magnesium has been demonstrated to be
associated with low bone density in pre- and postmenopausal
women [92, 94–96], and magnesium intake is found to be
positively correlated with a greater bone mineral density in
both men and women [97]. Furthermore, magnesium sup-
plements have been shown to improve BMD in osteoporotic
women [98, 99] and in young people [100–102]. Moreover,
high dietary magnesium intake reduced prospectively the
risk of osteoporotic fractures in middle-aged men and
women [103]. The relationship between magnesium and
bone health can be explained by different mechanisms. Low
magnesium can lead to alteration of trabecular bone by
formation of large but fragile crystals [104]. Moreover, low
magnesium can reduce the vascular supply of bones [105]
and increase inflammatory cytokines [106], which can trigger
bone remodeling and osteopenia. Furthermore, reduced
body magnesium can cause a reduction in PTH levels,
increase in tissue resistance to PTH, and decrease in vitamin
D levels [92]. On the other hand, hypermagnesemia has been
associated with osteopenia and osteoporosis in postmeno-
pausal women and people with chronic kidney diseases [92].
10.4. Magnesium-Dependent Vitamin D-Resistant Rickets.
Magnesium acts as a cofactor for binding of vitamin D to
its transport protein (vitamin D-binding protein), and it
is required for conversion of vitamin D into the active
form in the liver and the kidneys [2]. 1,25-Dihydroxyvita-
min D has been shown to stimulate the absorption of
magnesium from the intestines. Magnesium deficiency can
cause magnesium-dependent vitamin D-resistant rickets by
reducing the synthesis of vitamin D and impairing PTH
function [2]. Adequate replacement of magnesium is essen-
tial for the treatment of magnesium-dependent rickets [107].
11. Hypo- and Hypermagnesemia in
Cardiovascular Health
Magnesium has an important role in the regulation of cardiac
rhythm, influencing vascular tone, peripheral vascular resis-
tance, and endothelial function [3]. Table 9 summarizes the
effect of magnesium on cardiovascular health [87, 108–111].
11.1. Risk of Arrhythmia. Hypomagnesemia is associated
with an increased risk of cardiac arrhythmia via the following
possible mechanisms: decreased effect of magnesium against
calcium at the atrioventricular node (AV node); low magne-
sium causes impairment of Na+/K+-ATPase, which decreases
the levels of intracellular potassium, increases intracellular
sodium, and creates a less negative resting membrane poten-
tial. Both mechanisms lead to unstable membrane potentials
and conduction of impulses and increase the susceptibility to
arrhythmia [112]. Changes in the electrocardiograms (ECG)
associated with hypomagnesemia vary according to the levels
of magnesium. Mild hypomagnesemia leads to sinus tachy-
cardia, high-peaked T waves, and ST segment depression,
while severe hypomagnesemia causes shortening of the PQ
interval, QRS duration, and QTc [113].
In a large scale population study, hypomagnesemia was
associated with an increase in the incidence of atrial fibril-
lation over a 20-year follow-up [114]. Hypomagnesemia
also increased the risk of atrial fibrillation postcardiac
surgery [115].
Table 9: Magnesium effects on the cardiovascular system.
Improvement in endothelial function.
Induction of direct and indirect vasodilation.
Improvement in blood pressure.
Beneficial effects on arrhythmias, inflammatory reactions,
and platelet aggregation.
Potential effect in improving exercise tolerance in patients with
stable coronary artery disease.
Improvement of insulin homeostasis and lipid metabolism.
Reduces platelets activation and thrombosis.
Reduces cellular ischemic injury by reducing calcium overload
in coronary arteries.
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Several studies have demonstrated the association
between low serum magnesium and an increased risk of pre-
mature ventricular contractions, ventricular tachycardia, and
polymorphic ventricular tachycardia (torsades de pointes)
[112, 116–119]. A RCT showed that oral magnesium supple-
mentation reduced the intensity of premature ventricular
and supraventricular arrhythmia in patients without under-
lying ischemic or structural heart disease [120].
Digoxin inhibits Na+/K+-ATPase causing an increase in
the intracellular concentration of sodium and calcium. Mag-
nesium is an essential cofactor for Na+/K+-ATPase, and
hence, magnesium deficiency can cause further increase in
intracellular sodium, while decreasing the intracellular potas-
sium [113]. Hypomagnesemia has been associated with
increased risk of digoxin toxicity [121], which can precipitate
life-threatening dysrhythmia in patients with normal digoxin
and potassium level [122, 123]. It has also been shown that
treatment with oral magnesium supplements may be associ-
ated with a reduction in ventricular ectopy in patients with
low serum magnesium treated with digoxin for chronic atrial
fibrillation [124].
11.2. Risk of Coronary Artery Disease. Experimental animal
models have demonstrated that magnesium deficiency pro-
motes atherosclerotic lesions in arteries, and the degree of
atherosclerotic lesions was inversely related to themagnesium
intake. Furthermore, low magnesium could cause endothelial
dysfunction and hypercoagulability and increase the deposi-
tion of lipids and calcium in atheromatous lesions [113].
In human studies, an inverse relationship has been
observed between dietary magnesium intake and serummag-
nesium levels and overall risk of cardiovascular diseases
[125–127]. A meta-analysis on more than 77,000 cases found
an inverse association between magnesium levels in the
drinking water and cardiovascular mortality risk [128].
Another meta-analysis reviewing 19 studies with a total of
532,979 participants showed that dietary magnesium intake
and serum magnesium concentrations were inversely associ-
ated with the risk of total cardiovascular events [111]. More-
over, hypomagnesemia was found to be associated with
increased risk of coronary artery disease in a study involving
13,922 healthy subjects followed up for 4–7 years [129].
Other small RCTs have shown that oral magnesium supple-
mentation reduced platelet-induced thrombosis [108] and
improved endothelial function [130].
With regard to acute ischemia, hypomagnesemia was
found to be associated with increased mortality and malig-
nant arrhythmia in patients admitted with acute myocardial
infraction. A large retrospective cohort study involving
10,806 patients with acute myocardial infraction found a U-
shaped relationship between the most recent magnesium
levels and mortality. Lowest mortality was seen with serum
magnesium levels of ∼0.74 to 0.83mmol/L [131]. However,
several RCTs have shown conflicting results regarding the
role of intravenous magnesium administration in reducing
mortality in patients with acute myocardial infarction
[132]. In a prospective study involving 414 patients with a
median follow-up of 24 months, hypomagnesemia was asso-
ciated with an increase in major adverse cardiac events in
patients treated with drug-eluting stents for acute myocardial
infarction [133].
Thus, there is strong evidence to support the role of mag-
nesium in the risk of developing coronary artery diseases.
Furthermore, treatment of hypomagnesemia is important in
the prevention of arrhythmia in patients with acute myocar-
dial ischemia. Previous research has suggested that consump-
tion of water with high amount of magnesium could decrease
mortality from cardiovascular disease by 30–35% [134]. Sup-
plementing drinking water with magnesium, 25 to 50ppm,
may provide protection against cardiovascular disease and
probably many other health problems [135–137].
11.3. Hypertension. Low dietary magnesium and hypomag-
nesemia might be a contributing factor in the pathophysiol-
ogy of hypertension. Magnesium reduces vascular tone and
resistance by enhancing vasodilator effect of nitric oxide,
antagonizing the vasoconstrictor effect of calcium, bradyki-
nin, angiotensin II, serotonin, and prostaglandin in F2α,
and protecting the vascular endothelium through its antiox-
idant effect [138]. Several clinical trials have been conducted
to study the effect of magnesium supplementation on the
blood pressure, and at present, there is no strong evidence
to support the use of magnesium supplementation in the rou-
tine management of hypertension [3, 113].
11.4. Magnesium and Preeclampsia. Intravenous magnesium
sulfate has been used to treat preeclampsia and eclampsia for
a long time. The underlying mechanisms of action can be
explained by the vasodilating effect of magnesium in the
vasculature and its protective role against oxidative dam-
age during severe preeclampsia [139]. Furthermore, the
anticonvulsant effect of magnesium can be explained by
the role of magnesium in blocking N-methyl-D-aspartate
(NMDA) receptors [3]. A recent meta-analysis concludes
that magnesium sulfate for treatment of preeclampsia can
reduce the risk of eclampsia by 50% [140].
11.5. Heart Failure. Patients with congestive heart failure are
more prone to having low serum levels of potassium and
magnesium due to multiple factors. These include poor
oral intake, impaired gastrointestinal absorption, chronic
overstimulation of the renin-angiotensin-aldosterone sys-
tem, and the use of medications such as diuretics [141].
Some studies indicate the prevalence of hypomagnesemia
in patients with heart failure to exceed 30% [141, 142].
A RCT has shown the association of hypomagnesemia
with increased rate of ventricular ectopic beats, couplets,
and episodes of nonsustained ventricular tachycardia in
inpatients with heart failure. When treated for hypomag-
nesemia using intravenous magnesium sulfate, the same
group had significantly reduced rate of arrhythmias [141].
A recent meta-analysis of seven prospective studies with total
5172 heart failure patients showed that hypermagnesemia
(≥1.05mmol/L) was associated with an increased risk of car-
diovascular mortality and all-cause mortality in elderly
patients with chronic heart failure and reduced left ventricu-
lar function. These findings were not observed in patients
with hypomagnesemia [143].
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12. Hypomagnesemia and
Neurological Diseases
Extracellular magnesium has an inhibitory role on NMDA
receptors, γ-aminobutyric acid (GABA) receptors, and gluta-
mate release from NMDA receptor-rich neurons [3, 144].
Low extracellular magnesium can result in an abnormal
opening of NMDA-coupled calcium channels, leading to
increased calcium influx, hyperexcitability of neurons,
and an increase in the production of toxic nitric oxide
radicals [3, 145].
12.1. Headache. Observational studies have concluded that
patients with migraine tend to have lower serum [146, 147]
and brain [148] magnesium when compared to healthy sub-
jects. Several mechanisms have been described to explain the
relationship between low magnesium levels and migraine.
Low magnesium levels can increase the aggregation of plate-
lets and promote the secretion of serotonin, resulting in vaso-
constriction which can trigger acute migraine. Furthermore,
low magnesium increases neuronal excitability and triggers
cortical spreading depression by increasing NMDA receptor
activation, intracellular calcium, glutamate secretion, and the
levels of extracellular potassium [147, 149]. Intravenous
magnesium has been shown to have a beneficial additive
effect in alleviating acute migraine [150, 151] and other types
of acute headaches [152, 153]. To this end, oral magnesium
supplements have been tried as a prophylactic agent for
migraine with a significant beneficial effect [154, 155]. A
recent quasi-experimental study including 70 patients con-
cluded that both intravenous magnesium sulfate and intrave-
nous caffeine can significantly reduce the severity of acute
migraine headache, with better improvements observed with
magnesium [145]. However, a meta-analysis on five RCTs
with 295 patients failed to find a significant beneficial effect
of magnesium sulfate in alleviating migraines, although
the results need to interpreted with caution given the small
sample size [156].
12.2. Seizures. Severe hypomagnesemia can cause a general-
ized tonic-clonic seizure in children and adults. Seizures are
usually preceded by symptoms related to neuromuscular irri-
tability and CNS hyperexcitability [157, 158]. Magnesium
sulfate has been used as a drug of choice for seizure manage-
ment, treatment, and prophylaxis in women with preeclamp-
sia and eclampsia [157, 159–161]. It is suggested that oral
magnesium supplements might have a beneficial effect
when used as an adjunctive medication in the treatment
of drug-resistant epilepsy [162]. The anticonvulsant effect
of magnesium can be explained by its role in inhibiting
NMDA glutamate receptors, increasing production of
vasodilator prostaglandins, and stabilizing the neuronal
membrane [157].
12.3. Stroke. Low magnesium intake is associated with an
increased risk of stroke in several observational studies
[163–165], which can be explained by the beneficial role of
magnesium in endothelial function, platelet aggregation,
blood pressure, and glycemic control as discussed in the
previous section. Patients suffering acute ischemic stroke
and admitted with low magnesium levels have an increased
inpatient mortality risk [166] and increased intensity of neu-
rological deficit [167]. This might be attributed to the cere-
bral vasoconstriction triggered by hypomagnesemia. On the
other hand, a large double-blinded RCT reported that intra-
venous magnesium sulfate administration for patients with
acute stroke within 2 hours of onset of stroke symptoms
had no impact on the improvement of disability outcomes
at 90 days of poststroke [168].
13. Hypomagnesemia and Respiratory Diseases
Several studies have indicated that dietary magnesium and
intravenous magnesium sulfate infusion were associated
with an improvement in lung function, as measured by
forced vital capacity (FVC) and forced expiratory volume
(FEV) [169, 170]. While the mechanism of action is not
entirely understood, it is possible that magnesium acts
via anti-inflammatory effect and reduces lung inflamma-
tion along with the role of magnesium in regulating
bronchoconstrictors such as acetylcholine (ACh) and his-
tamine, as well as the vasodilatory and the bronchodilatory
effect of magnesium [3].
13.1. Bronchial Asthma. A single dose of intravenous magne-
sium sulfate (1.2 g) has been recommended for the manage-
ment of acute severe and life-threatening exacerbation of
asthma [171]. A Cochrane review analyzing the findings of
14 RCTs including 2313 adult patients presented to the
Emergency Department with acute exacerbation of bronchial
asthma concluded that intravenous magnesium sulfate
reduced the need for hospital admission and improves lung
function test [172]. Another RCT also showed that the use
of inhaled isotonic magnesium as adjuvant therapy in treat-
ment of severe acute exacerbation of bronchial asthma was
associated significant improvement of FEV1 at 90 minutes
[173]. The role of magnesium in antagonizing the effect of
calcium and altering intracellular cAMP and thereby reduc-
ing the neutrophil respiratory burst is believed to be the
mechanism of action of magnesium sulfate, which helps in
controlling airway inflammation during asthma [174].
13.2. Chronic Obstructive Pulmonary Disease (COPD).Hypo-
magnesemia is associated with advanced chronic lung dis-
eases, increased severity of the disease, and the length of
hospital stay, according to observational studies [175, 176].
However, a systemic review of four RCTs has failed to show
any significant therapeutic effect of intravenous or inhaled
magnesium used in the treatment of COPD [177]. Overall,
there are only a few experimental trials evaluating the effect
of magnesium on COPD, and the existing trials have several
limitations [178]. Therefore, further studies are required to
elaborate the impact of magnesium on COPD.
14. Magnesium Disorders and Kidney Disease
The kidney has a very important role in magnesium homeo-
stasis. Mild and moderate renal impairment can increase the
fractional excretion of magnesium to compensate for the loss
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of glomerular filtration [179]. However, with advanced
chronic kidney disease (creatinine clearance< 30mL/min),
this compensatory mechanism fails to maintain the homeo-
stasis, resulting in hypermagnesemia [180]. In addition, mag-
nesium homeostasis can be affected by vitamin D, PTH, and
calcium abnormalities associated with advanced chronic
kidney disease. In peritoneal hemodialysis patients, the
use of higher concentration of magnesium dialysate can
cause hypermagnesemia [179, 180]. In contrast, hypomag-
nesemia might be observed in patients as a result of the
use of low magnesium dialysate, secondary to medications
used or as a result of an underlying medical problem such
as malnutrition or alcohol abuse [181]. Patients with chronic
kidney disease and hypomagnesemia may have higher risk of
osteoporosis [182], cardiovascular morbidity, and an all-
cause mortality [183].
15. Future Perspectives
Further research would be valuable in assessing the utility of
magnesium level as a marker of disease severity, especially in
hospitalized patients. More importantly, much previous
research focused on diseases caused by hypomagnesemia
and the therapeutic role of magnesium. However, many dis-
eases discussed in this review could be a reflection of the
modern magnesium-deficient diet. We suggest that more
focus should be on the preventive role of magnesium on alle-
viating the burden of disease.
16. Conclusion
Magnesium is an essential cation involved in numerous enzy-
matic reactions and important for many vital physiological
functions. Magnesium disorders, especially hypomagnese-
mia, are common in clinical settings and are associated with
many adverse health outcomes. Magnesium has been used
successfully in treatment of medical conditions such as
bronchial asthma, cardiac arrhythmia, eclampsia, and pre-
eclampsia, and oral magnesium supplements have indicated
beneficial health outcomes. Further research is needed to
evaluate to feasibility and effectiveness of magnesium supple-
mentation on overall morbidity and mortality.
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